Tuesday , April 13 2021

Specialty Pharma Journal Specialty, Precision & Technology

Breaking News

FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded
Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion
Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
Final Analysis of the Observational GioTag Study: Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive NSCLC
Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
FDA Approves Onureg, a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
FDA Accepts Vertex’s sNDA for Trikafta, Symdeko and Kalydeco for Additional CFTR Mutations
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

Tag Archives: cardiovascular diseases

December, 2016

12 December
Bayer and Versant Ventures Team up to Launch Stem Cell Therapy Company BlueRock Therapeutics with $225 Million Financing

LEVERKUSEN, Germany and BOSTON and NEW YORK and TORONTO and KYOTO, Japan, Dec. 12, 2016 /PRNewswire/ — Bayer AG and Versant Ventures today announced the launch of BlueRock Therapeutics, a next-generation regenerative medicine company that plans to develop best-in-class induced pluripotent stem cell (iPSC) therapies to cure a range of …
Share

April, 2015

6 April
Bristol-Myers Squibb Enters Gene Therapy Deal with uniQure

Today, Bristol-Myers Squibb (BMS) announced that it has entered into a deal with uniQure for its gene therapy technology platform. The companies said that they have entered into an agreement that provides BMS with exclusive access to uniQure’s technology platform for multiple targets in cardiovascular diseases, as well as the …
Share